Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Honey-impregnated Dressings in the Local Management of Pressure Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Information provided on the implementation of the study, its objectives, constraints and patient rights~* The patient, or his/her legal guardian, must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 12 weeks of follow-up~* Presence of one or more pressure ulcers at stages 2, 3 or 4 according to the European Pressure Ulcer Advisory Panel - National Pressure Ulcer Advisory Panel (EPUAP-NPUAP) classification~* Wound whose surface is between 1 cm\^2 and 15 cm\^2~* Wound present for more than 6 weeks~* Patient whose wound requires a modern dressing (that is to say, a bandage that is neither tulle nor gauze) without bactericidal agents or antibiotics~* No antibiotics for at least 7 days prior to inclusion (after inclusion, the patient can be treated with antibiotics if necessary, regardless of the indications)~Exclusion Criteria:~* Patient participating in or having participated in another interventional study in the previous 3 months or currently in a patient exclusion period determined by a previous study.~* Patient under judicial protection~* Failure to correctly inform the patient or his/her legal representative~* Patient (or his/her legal guardian) refusal to sign the consent~* The patient is pregnant, parturient, or breastfeeding~* Contraindications (or incompatible combination therapy) for a necessary treatment in this study~* Patient with an allergy to honey or propolis~* The patient's general condition suggests study exclusion before twelve weeks of follow-up~* Antibiotics received within 7 days prior to inclusion~* Active neoplastic lesion treated with radiation or chemotherapy~* Immunosuppressive therapy or other treatment which, in the judgment of the investigator, may interfere with the healing process~* Surgery planned within twelve weeks of inclusion~* Stage 1 wound according to the EPUAP-NPUAP classification~* Amputation wound~* Wound related to a surgical treatment or for which an act of revascularization is envisaged within twelve weeks of inclusion~* Malignant wound

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MELECTIS G (Type: EXPERIMENTAL): In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.~Intervention: Usual care Intervention: MELECTIS G
- Usual care (Type: ACTIVE_COMPARATOR): Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).~Intervention: Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues